Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1

Nicholaou, T., Ebert, L., Davis, I.D., Robson, N.C., Klein, O., Maraskovsky, E., Chen, W. and Cebon, J. (2006) Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunology and Cell Biology, 84(3), pp. 303-317. (doi: 10.1111/j.1440-1711.2006.01446.x)

Abstract

Since the early 1990s, numerous cancer Ag have been defined and for a handful of these there is now some clinical experience, which has made it possible to assess their value as targets for cancer immunotherapy. The cancer-testis Ag have been particularly attractive because their expression is limited to cancer and virtually no non-malignant cells apart from germ cells and trophoblast. Among these, NY-ESO-1 has been the focus of our attention. The exceptional immunogenicity of this Ag coupled with its widespread distribution among many cancer types make it a very good vaccine candidate, with the potential to be used in vaccines against many types of malignancies. This article reviews emerging knowledge about the biology of NY-ESO-1 and experience with the early clinical development of vaccines directed against NY-ESO-1. These early studies have yielded a wealth of information about the immunology of NY-ESO-1 and set the scene for future clinical strategies for immune targeting of cancer.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Robson, Dr Neil
• Authors: Nicholaou, T., Ebert, L., Davis, I.D., Robson, N.C., Klein, O., Maraskovsky, E., Chen, W., and Cebon, J.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Journal Name: Immunology and Cell Biology
• ISSN: 0818-9641